To include your compound in the COVID-19 Resource Center, submit it here.

Lilly's lasmiditan meets in second Phase III for acute migraine

Eli Lilly and Co. (NYSE:LLY) reported data from the Phase III SPARTAN trial in about 3,000 patients with disabling migraine showing that single doses of 50, 100 and 200 mg

Read the full 301 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE